On May 15, 2026, the Food and Drug Administration FDA approved Immgolis (golimumab-sldi) as an interchangeable biosimilar biological product to Simponi (golimumab) and Immgolis Intri (golimumab-sldi) as an interchangeable biosimilar biological product to Simponi Aria (golimumab) to treat rheumatoid arthritis and ulcerative colitis. Immgolis and Immgolis Intri are the first biosimilars approved for Simponi and Simponi Aria, respectively. Immgolis is administered by subcutaneous injection in a single-dose prefilled syringe and Immgolis Intri is administered as an intravenous infusion prepared from a single dose vial.
